Overview
WuXi AppTec, a leading global pharmaceutical, biotechnology and medical device open-access capability and technology platform, announced its acquisition of ResearchPoint Global (RPG).
RPG is a full-service contract clinical research organization providing a full range of services, including project management, site selection and management, safety and medical monitoring, clinical monitoring, data management, biostatistics, as well as medical writing, across all phases of clinical development, including multi-regional clinical trials.
RPG will become a wholly-owned subsidiary of WuXi, and will continue to focus on growing its core competences and providing better clinical development services.
Significance
RPG and WuXi’s existing China-based Clinical Development Service (“CDS”) team will be integrated into a business unit that will bring truly global and seamlessly integrated clinical development service to the customers.
The acquisition underscores a strategic step forward to expand WuXi’s clinical research capabilities in the United States and around the world, further strengthening WuXi’s integrated R&D capability platform.
This combination allows RPG to offer its customers a true global solution from Discovery to Regulatory Submission.
Crosstree’s Role
Crosstree Capital Partners acted as exclusive financial advisor to ResearchPoint Global (RPG).
Latest Deals
Myonex Acquired Creapharm's Clinical & Commercial Packaging and Bioservices Business Units to Expand Clinical Trial Supply Services and Gain of Foothold in Europe
.png)
Myonex Acquired SaveWay Compounding Pharmacy to Expand and Bolster its Clinical Trial Services Across the US
%20(1).png)
physIQ Acquired by Prolaio to Enhance its Next-Gen Connected Heart Care Technology for Clinical Care and Research
.png)
Continuum Clinical, a BC Worldwide company, Acquired by Spectrum Science, a Portfolio Company of Knox Lane, to Bolster Patient Engagement Capabilities
%20(NEW).png)
Yecuris Corporation Acquired by Janvier Group to Expand Preclinical Service Offering Internationally
.png)
Modular Devices, a Portfolio Company of O2 Investment Partners, Partners with Flow Clean Rooms and Supply to Bolster Existing Clean Room Manufacturing Capabilities and Expand Overall Offering
Alpha IRB Acquired by Sabai Global, a Portfolio Company of Thompson Street Capital, to Expand IRB Capabilities
Versiti Acquired Pearl Pathways to Expand Clinical Trial Services Capabilities
VaxTRIALS Acquired by Emmes, a portfolio company of New Mountain Capital, to Expand Vaccine and Clinical Trial Site Capabilities
Grant Avenue Capital Recapitalizes CREO
Monroe Biomedical Research Acquired by New Harbor Capital in a First Step to Build-out a Clinical Research Site Platform
SSI Strategy, a Portfolio Company of Amulet Capital Partners, Acquired NDA Group AB to Bolster Regulatory Affairs Consulting Capabilities and Expand Into the EU
Catalyst Clinical Research, a Portfolio Company of QHP Capital, Acquired Genpro Research to Expand Global Footprint and Deepen Service Offerings
Accel Research Sites Network Acquired by Alcanza Clinical Research, a portfolio company of Martis Capital, to Expand its Clinical Trial Site Network and Clinical Trial Execution Capabilities
Benchmark Research Acquired by IQVIA, combined with Avacare to Expand Vaccine and Clinical Trial Site Capabilities
Clinical Site Services and Patient Advertising Guru Acquired by American Clinical Research Services to Add Tech-Enabled Patient Recruitment Capabilities
ClinChoice Acquires CROMSOURCE to Expand CRO Capabilities Globally
anteris Acquired by Kymanox, a Portfolio Company of Westview Capital Partners, to Expand Injectable Combination Product Development Capabilities Globally
OpenClinica Completes Growth Recapitalization with Thompson Street Capital Partners to Accelerate Enablement of Clinical Trials
